SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

AKANDA CORP.
Date: Sept. 24, 2025 · CIK: 0001888014 · Accession: 0000000000-25-010427

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-290367

Date
September 24, 2025
Author
Division of
Form
UPLOAD
Company
AKANDA CORP.

Letter

Re: Akanda Corp. Registration Statement on Form F-1 Filed September 18, 2025 File No. 333-290367 Dear Katie Field:

September 24, 2025

Katie Field Interim Chief Executive Officer and Executive Director Akanda Corp. 100 King St. W, Suite 1600 Toronto, ON M5X 1G5 , Canada

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Samantha M. Guido

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 September 24, 2025

Katie Field
Interim Chief Executive Officer and Executive Director
Akanda Corp.
100 King St. W, Suite 1600
Toronto, ON M5X 1G5 , Canada

 Re: Akanda Corp.
 Registration Statement on Form F-1
 Filed September 18, 2025
 File No. 333-290367
Dear Katie Field:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Alan Campbell at 202-551-4224 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Samantha M. Guido
</TEXT>
</DOCUMENT>